Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.68 |
| ▸ | ATR | Q13535 | 5/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.46 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908597 | 0.94 | BTK (0.61) | BTKPIK3CDATREGFRLCK | |
| SCHEMBL16655479 | 0.90 | PIK3CD (0.68) | BTKPIK3CDATREGFRLCK | |
| SCHEMBL16655386 | 0.88 | PIK3CD (0.77) | BTKPIK3CDATREGFRLCK | |
| SCHEMBL16655658 | 0.85 | ATR (0.71) | BTKPIK3CDATRLCKSRC | |
| SCHEMBL16665786 | 0.84 | PIK3CD (0.61) | BTKPIK3CDATREGFR | |
| SCHEMBL16655625 | 0.84 | PIK3CD (0.61) | BTKPIK3CDATREGFR | |
| SCHEMBL16656113 | 0.84 | BTK (0.49) | BTKPIK3CDATREGFRLCK | |
| SCHEMBL16655953 | 0.83 | PIK3CD (0.84) | BTKPIK3CDATREGFRSRC | |
| SCHEMBL16655966 | 0.83 | BTK (0.66) | BTKPIK3CDATRLCKSRC | |
| SCHEMBL16655939 | 0.82 | PIK3CD (0.69) | BTKPIK3CDATREGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | BTK 1/4885PIK3CD 2/4885ATR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.